Foghorn Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
FHTX$1.90-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity Deficit
(In thousands, except share amounts)
| Common Stock · AdditionalPaid-inCapital · AccumulatedOtherComprehensiveLoss · AccumulatedDeficit · TotalStockholders’Equity(Deficit) | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balances at December 31, 2021 | 41,299,720 | $4 | $361,133 | $(10) | $(264,256) | $96,871 |
| Issuance of common stock upon exercise of stock options and employee stock purchase plan | 503,716 | — | 1,763 | — | — | 1,763 |
| Stock-based compensation expense | — | — | 14,336 | — | — | 14,336 |
| Unrealized losses on marketable securities | — | — | — | (3,976) | — | (3,976) |
| Net loss | — | — | — | — | (108,882) | (108,882) |
| Balances at December 31, 2022 | 41,803,436 | 4 | 377,232 | (3,986) | (373,138) | 112 |
| Issuance of common stock upon exercise of stock options and employee stock purchase plan | 478,604 | $— | 1,778 | — | — | 1,778 |
| Stock-based compensation expense | — | — | 16,186 | — | — | 16,186 |
| Unrealized gains on marketable securities | — | — | — | 3,160 | — | 3,160 |
| Net loss | — | — | — | — | (98,426) | (98,426) |
| Balances at December 31, 2023 | 42,282,040 | $4 | $395,196 | $(826) | $(471,564) | $(77,190) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.